Uniwersytecki Szpital Kliniczny W Bialymstoku
- Address
- lock Available on a paid plan
Uniwersytecki Szpital Kliniczny W Bialymstoku - Metabolic and Obesity Research
Uniwersytecki Szpital Kliniczny W Bialymstoku is actively engaged in advanced metabolic research, with particular emphasis on innovative therapeutic approaches for weight management and related conditions. The center participates in international multi-center trials investigating novel pharmacological interventions for patients struggling with excess weight.
- Obesity treatment and management studies
- Investigation of novel weight loss therapeutics including retatrutide
- Research in metabolic conditions associated with overweight
The institution's research portfolio includes comprehensive evaluation of both efficacy and safety outcomes in obesity and overweight management, extending to patients with comorbid conditions such as knee osteoarthritis. This integrated approach positions the center as a key contributor to understanding the broader health impacts of weight management interventions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 208 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 206 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 51 by active trials.
- 1Novo Nordisk A/S5active
lock +50 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S15trials
lock +27 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersytecki Szpital Kliniczny W Bialymstoku
lock Showing 1 of 156 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Budiodarone in Subjects with Non-permanent Atrial Fibrillation | Xyra LLC | Phase IV | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 208 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 15 | Unknown | 2019-02-21 | 2026-05-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.